Dr. Marilyn C. Roberts and Dr. Stefan Schwarz have contacted the authors of the original publication with several comments and suggestions to better harmonize the correct nomenclature of the antibiotic resistance genes, as the gene names were not always correctly presented in the various tables given.
Authors often pick their own gene names which in many cases have been approved for use for other genetically distinct genes or give names to determinants which were already given an approved designated name. Therefore, we (Dr. Marilyn C. Roberts and Dr. Stefan Schwarz and Dr. Henk J. M. Aarts on behalf of the authors of the original publication) would like to present here the correct nomenclature and mechanistic features of the antibiotic resistance genes belonging to the following classes: Aminoglycosides (Table 1) , Phenicols (Table 3) , Macrolides-LincosamidesStreptogramin B (Table 4) , Quinolones (Table 5) , Tetracyclines (Table 6) , and Trimethoprim (Table 7) . In addition some additional information is given on the various classes of antibiotic resistance genes as also a section regarding the antibiotic class Oxazolidinones has been added. Table 2 was correctly displayed by van Hoek et al. (2011) but has been updated.
To the subsection dealing with the "Resistance mechanisms" of the AMINOGLYCOSIDES we would like to add that to date six additional methylases have been reported, i.e., npmA, rmtA, rmtB, rmtC, rmtD, and rmtE (Courvalin, 2008; Doi et al., 2008; Davis et al., 2010) . Futhermore, that within the three major classes (AAC, ANT, and APH) an additional subdivision can be made based on the enzymes' target sites within the aminoglycoside molecules: i.e., there are four acetyltransferases: AAC(1), AAC(2 ), AAC(3), and AAC(6 ); five nucleotidyltransferases: ANT(2 ), ANT(3 ), ANT(4 ), ANT(6) , and ANT(9); and seven phosphotransferases: APH(2 ), APH(3 ), APH(3 ), APH(4), APH(6), APH(7 ), and APH(9).
To the subsection β-LACTAM, Resistance, mechanisms we would like to add that in recent years acquired genes encoding ESBLs have become a major concern (Bradford, 2001 ). Over time, the genes for the parent enzymes bla TEM−1 , bla TEM−2 , and bla SHV−1 have undergone point mutations which resulted in amino acid substitutions that changed the substrate spectrum to that of ESBLs, starting with bla TEM−3 and bla SHV−2 (Bradford, 2001 ).
Because chloramphenicol is not an actual antibiotic class the subsection of CHLORAMPHENICOL should be called PHENICOLS. Concerning the history of PHENICOLS, it is worthwhile to know the first antibiotic, chloramphenicol, originally referred to as chloromycetin, was isolated already in 1947 from Streptomyces venezuelae (Ehrlich et al., 1947) .
Besides the inactivating enzymes (chloramphenicol acetyltransferases), there are also reports on other phenicol resistance systems, such as the inactivation by phosphotransferases, mutations of the target site, permeability barriers, and efflux systems (Schwarz et al., 2004) . Of the latter mechanism, cmlA and floR are the most commonly known genes in Gram-negative bacteria (Bissonnette et al., 1991; Briggs and Fratamico, 1999) .
The macrolides (subsection MACRO-LIDES -LINCOSAMIDES -STREPTO-GRAMIN B) have a similar mode of antibacterial action, comparable antibacterial spectra and in part overlapping binding sites at the ribosome as two other antibiotic classes, i.e., lincosamides and streptogramin antibiotics (comprising streptogramin A and B compounds that act synergistically). Consequently, these antibiotics, although chemically distinct, have been clustered together as MLS antibiotics (Roberts, 1996) . Macrolides, lincosamides and streptogramins all inhibit protein synthesis by binding to the 50S ribosomal subunit of bacteria (Weisblum, 1995; Roberts, 2002) .
To Resistance mechanisms of the subsection MACROLIDES-LINCOSAMIDES-STREPTOGRAMIN B. Shortly after the introduction of erythromycin into clinical setting in the 1950s, bacterial resistance to this antibiotic was reported for the first time in staphylococci (Weisblum, 1995) . Since then a large number of bacteria have been identified that are resistant to MLS due to the presence of various different genes. The resistance determinants responsible include rRNA methylases that modify the ribosomal target sites, ABC transporters, and efflux proteins of the Major Facilitator Superfamily, as well as genes for inactivating enzymes (Roberts et al., 1999; Roberts, 2008) . The latter group can be further Elbourne and Hall (2006) , Magnet and Blanchard (2005) , Partridge et al. (2009), Ramirez and Tolmansky (2010) , Shaw et al. (1993) , Vakulenko and Mobashery (2003) Weldhagen et al. (2006 (Saladin et al., 2002; Olson et al., 2005) . Roberts and Schwarz (2009) , Schwarz et al. (2004) , and nucleotide BLAST searches. § Partial sequence. Table 4 ; Kehrenberg et al., 2007) . Table 3 ; Kehrenberg et al., 2007) . a Esterase, b Lyase, c Transferase, and d Phosphorylase. subdivided into esterases, lyases, phosphorylases, and transferases ( Table 4) . The most common mechanism of MLS B resistance is due to the presence of rRNA methylases, encoded by the erm genes. These enzymes methylate the adenine residue(s) resulting in MLS B resistance. The methylated adenine(s) prevents the drugs from binding to the 50S ribosomal subunit. The other two mechanisms efflux and enzymatic inactivation result in resistance to only 1 or 2 classes of antibiotics belonging to the MLS group.
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$ The multidrug resistance gene cfr confers resistance against phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A (see
There are currently 77 MLS resistance genes recognized. A new MLS gene must have <79% amino acid identity with all previously characterized MLS genes before receiving a unique name (Roberts et al., 1999; Roberts, 2008) .
For an actual list of the MLS acquired resistance genes we refer to the website of Dr. Marilyn Roberts, http://faculty. washington.edu/marilynr/.
In addition to the subsection of QUINOLONES currently five families of qnr genes have been reported; qnrA (7 subtypes), qnrB (59 subtypes), qnrC (1 subtype), qnrD (1 subtype), and qnrS (8 subtypes) (Jacoby et al., 2008; Grape (2006) , Partridge et al. (2009) , and nucleotide BLAST searches.
mechanism since its sequence does not appear to be related to either efflux or RPPs, nor to the inactivation enzymes. The efflux and RPP encoding genes are found in members of Gram-positive, Gram-negative, aerobic, as well as anaerobic bacteria. In contrast, the enzymatic tetracycline inactivation mechanism has so far only been identified in Gram-negative bacteria. The tet(M) has the broadest host range of all tetracycline resistance genes, whereas tet(B) gene has the widest range among the Gram-negative bacteria. In recent years published data indicate that there are increasing numbers of Gramnegative bacteria that carry tet genes originally identified in Gram-positive bacteria (Roberts, 2002) . To the subsection TRIMETHOPRIM, Resistance mechanisms. Initially, the acquired DHFRs fell into two distinct families A and B, encoded by the dfrA and dfrB genes (Howell, 2005) . Up to now 6 plasmid-mediated families can be distinguished with relatively few dfr determinants originating from Grampositive bacteria ( Table 7) . The dfrK and dfrA28 genes are the newest additions to the trimethoprim resistance determinant family (Kadlec and Schwarz, 2009; Kadlec et al., 2011) . In contrast to the latest reported DHFRs, the oldest families, dfrA and dfrB, each contain several members (Roberts, 2002; Levings et al., 2006) . For example, the dfrA group accomodates over 30 published genes; however, unpublished, dfrA variants are also present in the public DNA libraries and some genes apparently have changed nomenclature (Table 7) .
Furthermore, we suggest an additional section concerning oxazolidinones.
OXAZOLIDINONES HISTORY AND ACTION MECHANISM
Linezolid is to date the only FDA-approved oxazolidinone (Shaw and Barbachyn, 2011) . It was approved in 2000 for the treatment of serious infections caused by Gram-positive bacteria resistant to other antibiotics, such as vancomycin-resistant enterococci (VRE) and methicillinresistant Staphylococcus aureus (MRSA) (Long and Vester, 2012) . As such linezolid is considered one of the last resort antimicrobial agents in human medicine. It has not been approved for use in veterinary medicine. Oxazolidinones bind at the P site of the ribosome and inhibit the formation of the initiation complex, which consists of mRNA, f-Met tRNA, and the 50S ribosomal subunit (Shaw and Barbachyn, 2011; Long and Vester, 2012) .
RESISTANCE MECHANISM
Various mutations located in the peptidyl transferase loop of domain V of 23S rRNA as well as mutations in the genes for the ribosomal proteins L3 and L4, all associated with resistance to oxazolidinones, have been identified (reviewed by Long and Vester, 2012) . A single gene, cfr, has been identified to confer transferable resistance to oxazolidinones. This gene codes for a methyltransferase that targets A2503 in 23S rRNA (Kehrenberg et al., 2005) . Besides oxazolidinone resistance, it also confers resistance to phenicols, lincosamides, pleuromutilins, and streptogramin A antibiotics. Although initially identified in coagulase-negative staphylococci of animal origin, the gene cfr has now been detected in a wide variety of staphylococci of human and animal origin, including a Panton-Valentin leukocidin-positive MRSA USA300 (Shore et al., 2010) and livestock-associated MRSA ST398 (Kehrenberg et al., 2009 ). More recently, the cfr gene has also been identified in Bacillus spp. (Dai et al., 2010) and Enterococcus faecalis (Liu et al., 2012) , but also in Gram-negative bacteria, such as Proteus vulgaris (Wang et al., 2011) and Escherichia. coli .
Plasmids and insertion sequences seem to play an important role in the spread of this gene across species and genus boundaries.
